The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast

Adv Ther. 2024 Mar;41(3):915-927. doi: 10.1007/s12325-023-02763-z. Epub 2024 Feb 2.

Authors

Peter C Black¹, Bernhard J Eigl^{2

3}

Affiliations

¹ Department of Urologic Sciences, University of British Columbia, Level 6, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada. [email protected].
² Department of Urologic Sciences, University of British Columbia, Level 6, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada.
³ Department of Medical Oncology, University of British Columbia, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

No abstract available

Keywords: BCG vaccine; Disease management; Immune checkpoint inhibitors; Non-muscle-invasive bladder neoplasms; Urology.

MeSH terms

Adjuvants, Immunologic
Humans
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Non-Muscle Invasive Bladder Neoplasms*
Urinary Bladder Neoplasms* / drug therapy

Substances

Adjuvants, Immunologic